vs
Side-by-side financial comparison of Eastern Bankshares, Inc. (EBC) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $168.4M, roughly 1.8× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 1.7%). Over the past eight quarters, Eastern Bankshares, Inc.'s revenue compounded faster (38.6% CAGR vs 10.6%).
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
EBC vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $168.4M |
| Net Profit | $65.3M | — |
| Gross Margin | — | — |
| Operating Margin | — | 50.6% |
| Net Margin | 22.1% | — |
| Revenue YoY | 1.7% | 143.7% |
| Net Profit YoY | 289.8% | — |
| EPS (diluted) | $0.29 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $295.9M | — | ||
| Q4 25 | $37.5M | $168.4M | ||
| Q3 25 | $241.5M | $87.3M | ||
| Q2 25 | $244.9M | $82.4M | ||
| Q1 25 | $31.1M | $65.0M | ||
| Q4 24 | $216.5M | $69.1M | ||
| Q3 24 | $203.4M | $51.6M | ||
| Q2 24 | $154.0M | $73.8M |
| Q1 26 | $65.3M | — | ||
| Q4 25 | $99.5M | — | ||
| Q3 25 | $106.1M | $-31.3M | ||
| Q2 25 | $100.2M | $-12.7M | ||
| Q1 25 | $-217.7M | $-40.5M | ||
| Q4 24 | $60.8M | — | ||
| Q3 24 | $-6.2M | $-29.5M | ||
| Q2 24 | $26.3M | $-61.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 50.6% | ||
| Q3 25 | 38.9% | -11.4% | ||
| Q2 25 | 41.0% | 8.6% | ||
| Q1 25 | -590.9% | -34.0% | ||
| Q4 24 | 33.3% | -6.4% | ||
| Q3 24 | -1.6% | -31.0% | ||
| Q2 24 | 24.7% | 3.5% |
| Q1 26 | 22.1% | — | ||
| Q4 25 | 265.6% | — | ||
| Q3 25 | 44.0% | -35.9% | ||
| Q2 25 | 40.9% | -15.4% | ||
| Q1 25 | -699.2% | -62.2% | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | -3.0% | -57.2% | ||
| Q2 24 | 17.1% | -83.9% |
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.48 | $0.32 | ||
| Q3 25 | $0.53 | $-0.16 | ||
| Q2 25 | $0.50 | $-0.06 | ||
| Q1 25 | $-1.08 | $-0.21 | ||
| Q4 24 | $0.29 | $-0.14 | ||
| Q3 24 | $-0.03 | $-0.15 | ||
| Q2 24 | $0.16 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $551.7M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.3B | $-302.0M |
| Total Assets | $30.6B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $551.7M | — | ||
| Q4 25 | $507.6M | $167.9M | ||
| Q3 25 | $703.4M | $92.4M | ||
| Q2 25 | $948.3M | $86.1M | ||
| Q1 25 | $609.0M | $114.6M | ||
| Q4 24 | $1.9B | $144.8M | ||
| Q3 24 | $1.7B | $144.7M | ||
| Q2 24 | $1.4B | $189.3M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $-302.0M | ||
| Q3 25 | $3.8B | $-451.4M | ||
| Q2 25 | $3.7B | $-433.5M | ||
| Q1 25 | $3.6B | $-426.2M | ||
| Q4 24 | $3.6B | $-388.7M | ||
| Q3 24 | $3.7B | $-370.2M | ||
| Q2 24 | $3.0B | $-344.2M |
| Q1 26 | $30.6B | — | ||
| Q4 25 | $30.6B | $465.9M | ||
| Q3 25 | $25.5B | $364.0M | ||
| Q2 25 | $25.5B | $347.1M | ||
| Q1 25 | $25.0B | $324.0M | ||
| Q4 24 | $25.6B | $343.8M | ||
| Q3 24 | $25.5B | $314.1M | ||
| Q2 24 | $21.0B | $352.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $432.4M | $45.2M | ||
| Q3 25 | $157.1M | $-4.3M | ||
| Q2 25 | $123.9M | $-31.4M | ||
| Q1 25 | $47.3M | $-22.6M | ||
| Q4 24 | $283.8M | $-35.0M | ||
| Q3 24 | $108.3M | $-35.3M | ||
| Q2 24 | $54.3M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 4.35× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.67× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBC
| ALLL / total nonperforming loans ("NPLs") | $238.2M | 80% |
| Other | $51.6M | 17% |
| Return on average shareholders' equity | $6.1M | 2% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
